Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.116034 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Kazumasa Yamamoto und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Oxaliplatin, Antineoplastic Combined Chemotherapy Protocols, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center Japan, National Cancer Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: The combination of oxaliplatin-based doublet chemotherapy and molecular targeted agents is the standard first-line treatment for metastatic colorectal cancer. However, the temporal evolution of associated treatment outcomes is unclear. We utilized Aide et Recherche en Cancérologie Digestive (ARCAD) data to evaluate the chronological changes in clinical outcomes associated with this regimen in metastatic colorectal cancer. METHODS: An individual patient data meta-analysis was performed using data from 5424 patients enrolled in 13 randomized controlled trials within the ARCAD database between 2004 and 2017. Eligible patients received oxaliplatin-based chemotherapy combined with bevacizumab or anti-epidermal growth factor receptor antibodies. Intervals of 2004-2008, 2009-2013, and 2014-2017 were examined. Overall, progression-free, and post-progression survivals were analyzed using Kaplan-Meier and Cox proportional hazards models adjusted for key prognostic factors. RESULTS: Median overall survival improved over time, from 21.4 months (2004-2008) to 28.6 months (2009-2013) and 29.7 months (2014-2017). Similar trends were observed for progression-free and post-progression survivals. Multivariable analysis confirmed the treatment period as an independent prognostic factor for overall and progression-free survivals. Subgroup analyses revealed improvements in overall survival for left-sided and RAS wild-type tumors, whereas minimal gains were found for right-sided or RAS-mutated tumors. Increased use of subsequent therapies contributed to prolonged post-progression survival. CONCLUSIONS: We demonstrated progressive improvements in survival outcomes for patients with metastatic colorectal cancer receiving first-line oxaliplatin-based chemotherapy plus molecular targeted agents. The findings highlight the importance of biomarker-driven treatment strategies and the evolving role of subsequent therapies in optimizing clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan; Department of Data Science, National Cancer Center Hospital East, Chiba, Japan.
- Department of Data Science, National Cancer Center Hospital East, Chiba, Japan.
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Oita University Faculty of Medicine, Oita, Japan.
- Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan.
Förderung
- National Cancer Center Japan
- National Cancer Center
Zitieren
APA
Yamamoto, K., Bando, H., Misumi, T., Nishikawa, T., Wakabayashi, M., Yamazaki, K., Maehara, Y., Oki, E., Saltz, L. B., Douillard, J. Y., Punt, C. J., Koopman, M., Van Cutsem, E., Bokemeyer, C., Venook, A. P., Heinemann, V., Cremolini, C., Randolph Hecht, J., Schmoll, H. J., …, & Yoshino, T. (2025). Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116034
Vancouver
Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, et al. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.116034
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Kazumasa and Bando, Hideaki and Misumi, Toshihiro and Nishikawa, Tomomi and Wakabayashi, Masashi and Yamazaki, Kentaro and Maehara, Yoshihiko and Oki, Eiji and Saltz, Leonard B and Douillard, Jean-Yves and Punt, Cornelis Ja and Koopman, Miriam and Van Cutsem, Eric and Bokemeyer, Carsten and Venook, Alan P and Heinemann, Volker and Cremolini, Chiara and Randolph Hecht, J and Schmoll, Hans-Joachim and Nakayama, Goro and Lenz, Heinz-Josef and Andre, Thierry and Shi, Qian and de Gramont, Aimery and Shitara, Kohei and Yoshino, Takayuki},
title = {Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.116034}
}
EUVIMED